236 related articles for article (PubMed ID: 24615603)
1. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy.
Bednarski BK; Habra MA; Phan A; Milton DR; Wood C; Vauthey N; Evans DB; Katz MH; Ng CS; Perrier ND; Lee JE; Grubbs EG
World J Surg; 2014 Jun; 38(6):1318-27. PubMed ID: 24615603
[TBL] [Abstract][Full Text] [Related]
2. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
Rodriguez-Galindo C; Krailo MD; Pinto EM; Pashankar F; Weldon CB; Huang L; Caran EM; Hicks J; McCarville MB; Malkin D; Wasserman JD; de Oliveira Filho AG; LaQuaglia MP; Ward DA; Zambetti G; Mastellaro MJ; Pappo AS; Ribeiro RC
J Clin Oncol; 2021 Aug; 39(22):2463-2473. PubMed ID: 33822640
[TBL] [Abstract][Full Text] [Related]
7. Surgery for recurrent adrenocortical carcinoma: A multicenter retrospective study.
Simon G; Pattou F; Mirallié E; Lifante JC; Nominé C; Arnault V; de Calan L; Caillard C; Carnaille B; Brunaud L; Laplace N; Caiazzo R; Blanchard C
Surgery; 2017 Jan; 161(1):249-256. PubMed ID: 27855966
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
[TBL] [Abstract][Full Text] [Related]
10. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
12. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
Miller BS; Gauger PG; Hammer GD; Giordano TJ; Doherty GM
Langenbecks Arch Surg; 2010 Sep; 395(7):955-61. PubMed ID: 20694732
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience.
Loncar Z; Djukic V; Zivaljevic V; Pekmezovic T; Diklic A; Tatic S; Dundjerovic D; Olujic B; Slijepcevic N; Paunovic I
BMC Urol; 2015 May; 15():43. PubMed ID: 26013141
[TBL] [Abstract][Full Text] [Related]
14. Adrenocortical carcinoma: effect of hospital volume on patient outcome.
Lombardi CP; Raffaelli M; Boniardi M; De Toma G; Marzano LA; Miccoli P; Minni F; Morino M; Pelizzo MR; Pietrabissa A; Renda A; Valeri A; De Crea C; Bellantone R
Langenbecks Arch Surg; 2012 Feb; 397(2):201-7. PubMed ID: 22069043
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
Sabolch A; Else T; Griffith KA; Ben-Josef E; Williams A; Miller BS; Worden F; Hammer GD; Jolly S
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):252-9. PubMed ID: 25754631
[TBL] [Abstract][Full Text] [Related]
16. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease.
Asare EA; Wang TS; Winchester DP; Mallin K; Kebebew E; Sturgeon C
Surgery; 2014 Dec; 156(6):1378-85; discussion 1385-6. PubMed ID: 25456914
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
[TBL] [Abstract][Full Text] [Related]
18. The role of surgery in the management of recurrent adrenocortical carcinoma.
Erdogan I; Deutschbein T; Jurowich C; Kroiss M; Ronchi C; Quinkler M; Waldmann J; Willenberg HS; Beuschlein F; Fottner C; Klose S; Heidemeier A; Brix D; Fenske W; Hahner S; Reibetanz J; Allolio B; Fassnacht M;
J Clin Endocrinol Metab; 2013 Jan; 98(1):181-91. PubMed ID: 23150691
[TBL] [Abstract][Full Text] [Related]
19. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
20. National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
Tierney JF; Chivukula SV; Poirier J; Pappas SG; Schadde E; Hertl M; Kebebew E; Keutgen X
J Clin Endocrinol Metab; 2019 Dec; 104(12):5948-5956. PubMed ID: 31361313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
